01—Abstract
Summary
Summary of the 8-K filed April 23, 2025. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences (EW) reported first-quarter 2025 results that beat expectations on the top line and profitability.
Net sales rose 6.2% reported (7.9% adjusted for FX and acquisitions) to $1.41 billiona. TAVR sales grew 3.8% reported and 5.4% at constant currency, with the company citing stable pricing and strong SAPIEN 3 Ultra RESILIA performance. TMTT (mitral and tricuspid) was the standout, growing 58% to $115 million, driven by PASCAL and EVOQUE, and management raised its 2025 TMTT sales guidance to $530-550 million.
Surgical sales grew 1% to $251 millionb. Profitability was solid, with GAAP operating margin of 27.9% (29.1% adjusted) and GAAP diluted EPS of $0.62 (adjusted $0.64). Gross margin improved to 78.7%, and R&D fell to 18.0% of sales from 19.3% a year earlier, reflecting prioritized spending.
SG&A was 33.0% of sales, somewhat better than planned due to deferred spending that management flagged may shift later in the year. Cash of about $3.1 billionc against roughly $600 million of total debt gives a strong balance sheet. The 2025 outlook is mixed.
Total sales guidance rose to $5.7d-6.1 billion, largely on favorable FX, but management expects margin pressure from a weaker dollar, announced tariffs, and the expected JenaValve acquisition close. The company reaffirmed its 27-28% operating margin and $2.40-2.50 adjusted EPS guidance, and it projects Q2 sales of $1.45-1.53 billion. Investors should note that the guidance explicitly assumes current tariffs remain in place and that the filing discloses a pending Critical Care divestiture, with separation costs and a discontinued-operations loss in the quarter.
02—Key points
Key Highlights
- Q1 2025 net sales of $1.41B, up 6.2% reported and 7.9% adjusted, with TMTT (+58%) the fastest-growing segment
- TAVR sales of $1.05B grew 3.8% reported and 5.4% constant currency; management expects asymptomatic indication approval in Q2 2025
- TMTT guidance raised to $530-550M from $500-530M; SAPIEN M3 received CE Mark, the world's first transcatheter mitral valve replacement system
- GAAP diluted EPS of $0.62 (adjusted $0.64); operating margin 27.9% GAAP and 29.1% adjusted, aided by favorable mix and timing of variable expenses
- Total 2025 sales guidance raised by $100M to $5.7-6.1B on FX, while adjusted EPS guidance of $2.40-2.50 and 27-28% operating margin guidance were reaffirmed
- Margin headwinds flagged for 2025: weaker dollar, announced tariffs, and expected JenaValve acquisition close; guidance assumes current tariffs remain in effect
- Strong balance sheet with about $3.1B cash versus roughly $600M total debt; discontinued operations (Critical Care sale) produced a $7.2M loss in the quarter
03—Questions
Frequently Asked Questions
Did Edwards beat expectations in Q1 2025?
Based on the company's statements, yes on the top line and profitability. Management said TAVR constant-currency growth of 5.4% was better than expected, and SG&A and operating margin were better than planned. The filing does not include consensus estimates, so the size of any beat versus Wall Street expectations cannot be confirmed from this document.
Why did Edwards raise its sales guidance but not its EPS guidance?
The sales guidance increase of $100M reflects favorable foreign exchange movements, not stronger underlying demand. Management expects those gains to be offset by a weaker dollar, tariffs, and JenaValve-related costs, which pressure operating margin, so it kept the 27-28% operating margin and $2.40-2.50 adjusted EPS guidance unchanged.
What is driving the growth in TMTT?
TMTT grew 58% to $115M, led by PASCAL and EVOQUE adoption in the U.S. and Europe. The EVOQUE launch is progressing well, and the recent CE Mark for SAPIEN M3 adds a mitral replacement option. Management expects this growth to keep contributing meaningfully to company performance.
Are there risks investors should watch in the guidance?
Yes. Guidance assumes current tariffs remain in place for the rest of 2025, and the filing states that any tariff change or new tariffs could materially affect results. Margin pressure from FX, the expected JenaValve close, and the timing of deferred SG&A and variable expenses (some of which may land later in the year) are also factors to monitor.
04—Continue